- 10 December 2018 Genethon announces dosing of the first patient with Crigler–Najjar Syndrome
- 5 October 2018 Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
- 13 March 2018 AveXis Enters into Licensing Agreement with Genethon
Created in 1990 by AFM-TELETHON, Genethon is fully dedicated to the design and development of gene therapy treatments for rare diseases. Its objective is to provide these innovative treatments to patients affected with rare disorders.
Genethon is developing therapies for rare neuromuscular diseases, immune system or blood disorders, eye disorders and liver diseases.